Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO

Zoé L. E. van Kempen; Laura Hogenboom; Joep Killestein

doi:https://doi.org/10.1177/13524585211064441

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO

Zoé L. E. van Kempen, Laura Hogenboom, Joep Killestein

Research output: Contribution to journal › Comment/Letter to the editor › Academic

3 Citations (Scopus)

Original language	English
Pages (from-to)	693-695
Number of pages	3
Journal	MULTIPLE SCLEROSIS JOURNAL
Volume	28
Issue number	5
DOIs	https://doi.org/10.1177/13524585211064441
Publication status	Published - 1 Apr 2022

Access to Document

https://doi.org/10.1177/13524585211064441

Cite this

@article{c61c612c10d94236a71794e01e70b0cb,

title = "Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO",

author = "{van Kempen}, {Zo{\'e} L. E.} and Laura Hogenboom and Joep Killestein",

note = "Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Z.K. and L.H. report no disclosures. J.K. reports speaking and consulting relationships with Biogen, Genzyme, Merck, Novartis, Roche, Sanofi, and TEVA. Amsterdam UMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Sanofi,and TEVA.",

year = "2022",

month = apr,

day = "1",

doi = "https://doi.org/10.1177/13524585211064441",

language = "English",

volume = "28",

pages = "693--695",

journal = "MULTIPLE SCLEROSIS JOURNAL",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "5",

}

TY - JOUR

T1 - Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing

T2 - NO

AU - van Kempen, Zoé L. E.

AU - Hogenboom, Laura

AU - Killestein, Joep

N1 - Funding Information: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Z.K. and L.H. report no disclosures. J.K. reports speaking and consulting relationships with Biogen, Genzyme, Merck, Novartis, Roche, Sanofi, and TEVA. Amsterdam UMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Sanofi,and TEVA.

PY - 2022/4/1

Y1 - 2022/4/1

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122748779&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/34994665

U2 - https://doi.org/10.1177/13524585211064441

DO - https://doi.org/10.1177/13524585211064441

M3 - Comment/Letter to the editor

C2 - 34994665

SN - 1352-4585

VL - 28

SP - 693

EP - 695

JO - MULTIPLE SCLEROSIS JOURNAL

JF - MULTIPLE SCLEROSIS JOURNAL

IS - 5

ER -

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO

Access to Document

Other files and links

Cite this